314 related articles for article (PubMed ID: 37446214)
41. Community-acquired pneumonia: new management strategies for evolving pathogens and antimicrobial susceptibilities.
Klugman KP; Low DE; Metlay J; Pechere JC; Weiss K
Int J Antimicrob Agents; 2004 Nov; 24(5):411-22. PubMed ID: 15519470
[TBL] [Abstract][Full Text] [Related]
42. Failure of levofloxacin treatment in community-acquired pneumococcal pneumonia.
Endimiani A; Brigante G; Bettaccini AA; Luzzaro F; Grossi P; Toniolo AQ
BMC Infect Dis; 2005 Nov; 5():106. PubMed ID: 16307682
[TBL] [Abstract][Full Text] [Related]
43. Immunomodulatory agents in the treatment of community-acquired pneumonia: a systematic review.
Corrales-Medina VF; Musher DM
J Infect; 2011 Sep; 63(3):187-99. PubMed ID: 21763343
[TBL] [Abstract][Full Text] [Related]
44. What is the relevance of antimicrobial resistance on the outcome of community-acquired pneumonia caused by Streptococcus pneumoniae? (should macrolide monotherapy be used for mild pneumonia?).
Low DE
Infect Dis Clin North Am; 2013 Mar; 27(1):87-97. PubMed ID: 23398867
[TBL] [Abstract][Full Text] [Related]
45. Neutrophils in community-acquired pneumonia: parallels in dysfunction at the extremes of age.
Grudzinska FS; Brodlie M; Scholefield BR; Jackson T; Scott A; Thickett DR; Sapey E
Thorax; 2020 Feb; 75(2):164-171. PubMed ID: 31732687
[TBL] [Abstract][Full Text] [Related]
46. A review of clinical failures associated with macrolide-resistant Streptococcus pneumoniae.
Rzeszutek M; Wierzbowski A; Hoban DJ; Conly J; Bishai W; Zhanel GG
Int J Antimicrob Agents; 2004 Aug; 24(2):95-104. PubMed ID: 15288306
[TBL] [Abstract][Full Text] [Related]
47. Invasive Disease vs Urinary Antigen-Confirmed Pneumococcal Community-Acquired Pneumonia.
Ceccato A; Torres A; Cilloniz C; Amaro R; Gabarrus A; Polverino E; Prina E; Garcia-Vidal C; Muñoz-Conejero E; Mendez C; Cifuentes I; Puig de la Bella Casa J; Menendez R; Niederman MS
Chest; 2017 Jun; 151(6):1311-1319. PubMed ID: 28093269
[TBL] [Abstract][Full Text] [Related]
48. Circulating Pneumolysin Is a Potent Inducer of Cardiac Injury during Pneumococcal Infection.
Alhamdi Y; Neill DR; Abrams ST; Malak HA; Yahya R; Barrett-Jolley R; Wang G; Kadioglu A; Toh CH
PLoS Pathog; 2015 May; 11(5):e1004836. PubMed ID: 25973949
[TBL] [Abstract][Full Text] [Related]
49. Cardiotoxicity during invasive pneumococcal disease.
Brown AO; Millett ER; Quint JK; Orihuela CJ
Am J Respir Crit Care Med; 2015 Apr; 191(7):739-45. PubMed ID: 25629643
[TBL] [Abstract][Full Text] [Related]
50. Contradiction between in vitro and clinical outcome: intravenous followed by oral azithromycin therapy demonstrated clinical efficacy in macrolide-resistant pneumococcal pneumonia.
Kohno S; Tateda K; Kadota J; Fujita J; Niki Y; Watanabe A; Nagashima M
J Infect Chemother; 2014 Mar; 20(3):199-207. PubMed ID: 24477328
[TBL] [Abstract][Full Text] [Related]
51. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure.
Jacobs MR
Clin Infect Dis; 2002 Sep; 35(5):565-9. PubMed ID: 12173130
[No Abstract] [Full Text] [Related]
52. Role of beta-lactam agents in the treatment of community-acquired pneumonia.
Garau J
Eur J Clin Microbiol Infect Dis; 2005 Feb; 24(2):83-99. PubMed ID: 15696306
[TBL] [Abstract][Full Text] [Related]
53. Distribution of 13-Valent pneumococcal conjugate vaccine serotype streptococcus pneumoniae in adults 50 Years and Older presenting with community-acquired pneumonia in Israel.
Regev-Yochay G; Chowers M; Chazan B; Gonzalez E; Gray S; Zhang Z; Pride M
Hum Vaccin Immunother; 2018; 14(10):2527-2532. PubMed ID: 30188760
[TBL] [Abstract][Full Text] [Related]
54. Optimal therapy for severe pneumococcal community-acquired pneumonia.
Luján M; Gallego M; Rello J
Intensive Care Med; 2006 Jul; 32(7):971-80. PubMed ID: 16791660
[TBL] [Abstract][Full Text] [Related]
55. Association of levofloxacin resistance with mortality in adult patients with invasive pneumococcal diseases: a post hoc analysis of a prospective cohort.
Kang CI; Song JH; Kim SH; Chung DR; Peck KR; Thamlikitkul V; Wang H; So TM; Hsueh PR; Yasin RM; Carlos CC; Van PH; Perera J;
Infection; 2013 Feb; 41(1):151-7. PubMed ID: 22821428
[TBL] [Abstract][Full Text] [Related]
56. Macrolide Resistance in
Schroeder MR; Stephens DS
Front Cell Infect Microbiol; 2016; 6():98. PubMed ID: 27709102
[No Abstract] [Full Text] [Related]
57. Severe pneumococcal community-acquired pneumonia admitted to medical Tunisian ICU.
Belkhouja K; Ben Romdhane K; Ghariani A; Hammami A; M'hiri E; Slim-Saidi L; Ben Khelil J; Besbes M
J Infect Chemother; 2012 Jun; 18(3):324-31. PubMed ID: 22045164
[TBL] [Abstract][Full Text] [Related]
58. New antibiotics for community-acquired pneumonia.
Kollef MH; Betthauser KD
Curr Opin Infect Dis; 2019 Apr; 32(2):169-175. PubMed ID: 30640820
[TBL] [Abstract][Full Text] [Related]
59. Clinical outcome of invasive infections in children caused by highly penicillin-resistant Streptococcus pneumoniae compared with infections caused by penicillin-susceptible strains.
Gómez-Barreto D; Calderón-Jaimes E; Rodríguez RS; de los Monteros LE
Arch Med Res; 2000; 31(6):592-8. PubMed ID: 11257327
[TBL] [Abstract][Full Text] [Related]
60. Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience.
Baldo V; Cocchio S; Gallo T; Furlan P; Romor P; Bertoncello C; Buja A; Baldovin T
PLoS One; 2016; 11(11):e0166637. PubMed ID: 27846277
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
